This article has Open Peer Review reports available.
Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis
© The Author(s). 2016
Received: 11 July 2015
Accepted: 31 May 2016
Published: 7 June 2016
This study is a systematic review and meta-analysis of the diagnostic value of cardiovascular magnetic resonance (CMR) in cardiac amyloidosis (CA).
A wide variety of electronic databases were searched for studies of CMR that reported the diagnostic accuracy in patients with suspected CA. Research manuscripts were subjected to further systematic review and meta-analysis. Methodological evaluation was performed under the guidance of the Quality Assessment of Diagnostic Accuracy Studies −2 (QUADAS–2). Heterogeneity was assessed, and a random-effects model was used to assess the diagnostic effects of CMR on pooled sensitivity, pooled specificity, and summary receiver operating characteristics (SROC).
Seven studies that reported the performance of CMR for CA were included in the present systematic review, among which five studies (257 patients) that evaluated the diagnostic accuracy of late gadolinium enhancement (LGE) CMR were analyzed in the present meta-analysis. Heterogeneity was observed only in specificity. A summary sensitivity and specificity of 85 % (95 % CI: 77–91 %) and 92 % (95 % CI: 83–97 %) indicated a high diagnostic accuracy of LGE for CA. The AUC of SROC curve was 0.9530, suggesting that LGE is an effective way of diagnosing patients with possible cardiac involvement in amyloidosis.
LGE–CMR seems to have a relatively high diagnostic accuracy for amyloidosis patients with possible cardiac involvement. Combined CMR techniques may provide important information for the selection of suitable therapy.
KeywordsCardiac amyloidosis Cardiac magnetic resonance LGE Meta-analysis
The heart, like any organ in the body is susceptible to amyloid deposition. When this occurs in the heart, cardiac amyloidosis (CA) results. Although more than 30 types of protein can cause amyloid, only two types commonly deposit in the ventricular myocardium: amyloid light chain (AL) and amyloid transthyretin (ATTR). The heart is sometimes the only or early manifestation of systemic amyloidosis . Deposition of amyloid precursor proteins which then aggregate into amyloid fibrils in the extracellular space causes separation and distortion of the existing tissues and eventually causes irreversible cardiac dysfunction [2, 3]. This may occur in the myocardium, pericardium, small vessels and conduction system. The result is a restrictive cardiomyopathy with early diastolic dysfunction and later systolic dysfunction, conduction disease including sudden death and, occasionally ischaemia (with arterial involvement) .
CA is relatively under-diagnosed, especially wild type ATTR in older people with multisystem diseases. One potential reason is that the symptoms and signs of CA such as fatigue, low exercise tolerance and occasionally syncope with progressive diastolic and systolic dysfunction may be nonspecific, particularly in the early phases, resulting in delayed diagnosis and potentially missed therapeutic options. New treatments are available targeting the precursor proteins, including newer chemotherapy regimes and a variety of approaches to reduce transthyretin as a precursor, with further developments in the preclinical phase [5, 6]. For this reason, earlier diagnosis of CA is a major clinical goal .
Currently, the main steps in the clinical evaluation of patients with CA involve suspicion, detection, and classification. Suspicion may be raised by multisystem involvement (carpal tunnel, renal impairment etc.). Laboratory investigations may confirm the diagnosis, classify the CA, trace the specific protein precursor and appraise the stage of cardiac involvement including pump function . Currently, the most common examination procedures used to evaluate patients or conditions associated with CA include endomyocardial biopsy (EMB), electrocardiography (ECG), echocardiography and cardiac magnetic resonance (CMR) with some nuclear tests contributing (bone scintigraphy for ATTR, SAP scan for AL - but these are not widely available).
In CA, myocardial tissue histology stands as the gold standard, revealing the accumulation of amyloid proteins and fibers in the extracellular space. Histologically, EMB is initially stained using Congo Red where deposits may look pale red but show apple-green birefringence under cross-polarized light. Immunohistochemistry (IHC) or mass-spectrocopy can definitively subtype the amyloid fibrils . However, the invasive nature of EMB and related high-risk complications are barriers, as is the specialist nature of IHC and mass spectroscopy. Besides, as the lack of standardization on the definition of what constitutes CA, in some cases these is a need to use some ancillary imaging and clinical findings to ensure the pathological diagnosis. In addition, EMB is classified in the class IIa recommendation .
ECG Low -voltages is a classical feature of CA . But it provides a low -sensitivity and -specificity diagnosis of CA. This may be due in part to interference from other coexisting conditions, such as obesity, hypothyroidism, and pulmonary diseases, but up to 25 % of ATTR subjects have left ventricular hypertrophy. Under echocardiograph, the CA classical feature (a "brilliant" speckled appearance of myocardium) is a poor discriminator. Biventricular hypertrophy with disproportionate long axis impairment and restriction is more specific, but still has overlap, particularly in early disease .
CMR, a noninvasive mean of assessing amyloid burden, makes use of a superconducting magnet with ECG gating to measure the structure and function of the heart analogous to echocardiography. In addition, myocardial tissue characterisation detects tissue pathology . In particular, the late gadolinium enhancement (LGE) has a characteristic pattern in amyloid with subendocardial, later transmural LGE and difficulty nulling. This latter issue appears resolved with the phase-sensitive inversion recovery (PSIR) LGE sequence and it has potential to be a key technique for the diagnosis of patients with potential CA . Several studies have compared the diagnostic accuracy of CMR to that of EMB. However, they focused on different parameters and used different cutoff values in diagnostic tests, which limit their usefulness in the assessment of CA. For this reason, a systematic review was conducted to help evaluate the diagnostic aspects of CMR in patients with suspected CA.
This systematic review was carried out under the guideline of the Cochrane Collaboration’s Diagnostic Test Accuracy Group. Search strategies were developed to identify all the relevant studies published in the Pubmed, Embase, the Cochrane Library, Biosis Preview, ISI Web of Science, and China National Knowledge Infrastructure up to April 20, 2015. Medical subject headings and full text were searched for references to CA and magnetic resonance imaging to systematically locate these publications in any language. The details of the search strategies are provided in the additional files. The citations of eligible publications and reviews were also checked. Requirements were limited to human trials.
Study selection and data collection
The first author (LZ) conducted the initial literature search of titles and abstracts. Upon further scrutiny, two reviewers (LZ, ZT) led the retrieval of the full texts of relevant manuscripts independently. A third reviewer (QF) resolved all the disagreements and discrepancies that occurred during these processes through deep discussions. The following inclusion criteria were defined in advance: (1) a diagnostic accuracy test was included; (2) patients with at least suspected CA; (3) the diagnostic accuracy of CMR was evaluated regardless of acquisition protocol used; (4) EMB, clinical criteria, or both served as the reference tests; (5) the absolute numbers of true positive, false positive, true negative, and false negative results could be derived. All the articles that met these criteria were considered eligible. Duplicate and overlapping publications were excluded. Conference abstracts and research manuscripts that could not be obtained in their entirety or from which essential information was missing were also excluded. Diagnostic accuracy details, study methods, results, and additional information on patients and procedures were extracted from each primary study independently by two reviewers (LZ, ZT).
Assessment of risk of bias
Two reviewers (LZ, ZT) appraised the methodological quality based on the form suggested by the Quality Assessment of Diagnostic Accuracy Studies–2 (QUADAS–2), which has main parts: patient selection, index test, reference standards, and the flow and timing . Each part involves the assessment of risk of bias (low, high, or unclear) and first 3 parts also need to evaluate the clinical applicability. In cases of disagreement, 2 reviewers would reach a consensus after a thorough discussion with a third person (QF).
Statistical analyses were conducted using MetaDisc 1.4 software and Review Manager software version 5.3. First, heterogeneity in included manuscripts was assessed in terms of Cochran Q chi-square tests and I2 statistics. In cases of significant heterogeneity, the random-effects model was suitable to pool several parameters and sensitivity analysis was used to investigate potential sources targeting risk bias calculated by QUADAS–2. In other cases, the Mantel-Haenszel method was used to establish a fixed-effects model during the evaluation process. In cases of implicit threshold effects, the Spearman rank correlation was taken into consideration. Subgroup analysis determined if there was a correlation between sensitivity and specificity. Second, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratio (DOR), and their 95 % confidence intervals (CI) were estimated based on pooled sensitivity and specificity. In order to estimate the overall diagnostic effect, a summary receiver operating characteristic (SROC) curve was established, with pertinent areas. Whenever a study’s data contained zero counts, 0.5 was added as a continuity correction. Any significantly statistical calculating was at a two-sided 0.05 level.
There were 2 studies that did not clearly report that the EMB evaluation was blinded to CMR results [19, 21]. Another study stated it was done without blindness . In terms of the reference tests, some patients could not be classified clearly using clinical criteria alone [16, 21]. This kind of study involved high risk bias and uncertainty regarding use in the reference domain.
One study was discarded because of incomplete data for 2 × 2 table . The interval between CMR and the reference test were only clearly stated in 3 studies [17, 19, 21]. But these 3 studies together did not use the same reference test on all the patients. Some patients were evaluated by EMB and others were clinically assessed using ECG, echocardiography, or both. In the study by White, only 25 (28 %) patients with suspected CA were included in the final diagnostic evaluation .
Characteristics of included studies
Mean time intervala
Index measured using CMR
Hosch et al.
19 with newly diagnosed CA and 9 patients with systemic amyloidosis but without CA and 10 healthy, age-matched control
59 ± 6.1
T1 and T2 RT
Vogelsberg et al.
33 subjects with suspected CA
64 ± 13
Amyloid LGE pattern
Austin et al.
47 subjects with suspected CA
Ruberg et al.
28 patients with systemic AL amyloidosis
62 ± 11
EMB or clinical criteria
Karamitsos et al.
53 patients with systemic (primary) AL amyloidosis and 17 patients with aortic stenosis and 36 normal volunteers
63 ± 10c
Echocardiography and clinical features
Noncontrast T1 mapping; LGE
Aquaro et al.
59 patients with a previous diagnosis of systemic AL amyloidosis and 20 healthy control subjects
69 ± 10
Echocardiographic criteria and/or ECG criteria or EMB
SID; conventional LGE
White et al.
90 patients with suspected CA and 64 hypertensive patients with LVH
62 ± 13
Diagnostic performance of CMR for CA
Cardiac magnetic resonance evaluation of the included studies in the systematic review
Number of subjects
Index measured using CMR
Hosch et al.
Vogelsberg et al.
Austin et al.
Ruberg et al.
Karamitsos et al.
Noncontrast T1 mapping
Aquaro et al.
White et al.
Amyloidosis, when it affects the heart, has a poor prognosis. Better diagnostic tests would permit earlier detection and therefore targeted intervention to improve outcomes. Many modalities have been used in clinical settings to detect and evaluate CA . The most common methods are ECG and echocardiography. These tools are convenient and available in most medical facilities in which the EMB is not in common use. However, both methods detect CA with a relatively low accuracy. ECG evaluation is not suitable for patients with pulmonary disorders but many patients with cardiomyopathy, especially elderly patients, are likely to be involved in cardiopulmonary diseases. Echocardiography can detect the advanced cases . However, it cannot easily assess earlier cases or differentiate CA from hypertrophic cardiomyopathy because the characteristics in echocardiography are thick-walled ventricles with speckled myocardia [4, 23]. EMB is considered the gold standard in the diagnosis of CA. However, the unavailability, relatively high risks and clinical complications may hinder its widespread use in clinical settings. CMR provides a third option in the evaluation of the heart’s structure and assessment of its diastolic function. It is more precise and more accurate, which are regarded as the hallmarks of good non-invasive methods capable of assessing myocardial scars [13, 24].
The key advantage of using CMR to detect the CA is its unique ability to describe the characteristics of heart, which can be done particularly using LGE . After taking the gadolinium-based contrast, patients with CA presented typical global subendocardial enhancement patterns, which are closely associated with interstitial amyloid burden and often used to qualitatively detect focal fibrosis . This meta-analysis of LGE–CMR showed that the diagnostic accuracy increased with a summary sensitivity of 85 % and a summary specificity of 92 %. In terms of the heart tissue characterization, LGE can distinguish CA patients from healthy controls with a summary positive likelihood ratio of 7.481 (95 % CI: 2.835–19.739). The summary diagnostic odds ratio of 71.945 detected here (95 % CI: 23.552–219.77) indicated that expressed the test was more accurate in the differential diagnosis of CMR than other types of diagnosis. In this way, the values of LR+ and DOR favor of LEG–CMR in patients with suspected CA before EMB. Heterogeneity was observed across studies in terms of specificity, but not sensitivity. This could be partially due to the methodological quality of involved publications on reference tests choosing and flow and timing.
AL and ATTR are two types of amyloidosis typically associated with the heart. ATTR is often underdiagnosed and can be fatal. It also has particular variants in specific ethnic populations, which makes diagnosing and typing both necessary and challenging. Recently, several studies have reported that the new CMR techniques have better diagnostic accuracy in demonstrating the range of structural and functional changes in different types of CA . T1 mapping, a new technique measuring myocardial intrinsic signal, was found to diagnose AL and ATTR very accurately [28, 29]. Native T1 levels were higher in ATTR patients than in controls and the area under the AUC for ATTR and AL patients with possible or definite cardiac involvement was 0.85 (95 % CI: 0.79–0.92) . One study reviewed here evaluated the noncontrast myocardial T1, and the cut-off of 1020 ms yielded 92 % accuracy for identifying CA . T1–RT reported by Hosch also diagnosed CA with a high sensitivity (84 %) and specificity (>89 %) with a cut-off value of ≥1273 ms . The measurement of extracellular volume (ECV) measurement is popular in some centers [30, 31]. ECV is elevated in both AL and ATTR, which helps the evaluation of amyloid burden. It is also elevated in patients where routine examinations, including LGE, indicated no heart involvement. In the present systematic review, one study analyzed the myocardial signal intensity decay (SID) at the subendocardial level after gadolinium injection, showing a greater accuracy (96 %) and sensitivity (98 %) for CA assessment than LGE with a 269 HB threshold . T1 values were higher in AL amyloid than in ATTR, but ECV was higher in ATTR . This suggests that combined T1 and ECV techniques may attach more diagnostic accuracy to patients with cardiac involvement, quantify the amyloid burden to evaluate the pathologic conditions, and distinguish types of CA to help clinicians select the most appropriate treatment for each patient. When LGE combine with these advanced techniques, CMR could be a main technique for the diagnosis of patients with potential CA.
The current review has some limitations, which should be taken into consideration. The main one is the small number of studies included, which restricted deep exploration of potential sources of heterogeneity. The second limitation is that the typical amyloid LGE pattern varies across different series. Localized enhancement, diffuse transmural or patchy LGE enhancement was reported in different studies. In this review, only three studies described the diffuse, global subendocardial enhancement pattern as the amyloid pattern. The third limitation is that not all of the studies used the same reference tests. Not all patients underwent the same reference tests, introducing selection bias in the final results. Despite these limitations, the current work can present the current state of diagnostic tests of CMR for CA, which may help medical workers choose diagnostic methods efficiently and effectively.
The current work indicates that the LGE is more accurate in the diagnosis of CA, which makes it valuable in the detection of amyloid deposit. However, when considering clinical cost-effectiveness and patients with claustrophobia, implanted cardiac devices and renal failure, CMR application value in CA needs further investigation.
AL, Amyloid light chain; ATTR, Amyloid transthyretin; AUC, Area under the curve; CA, Cardiac amyloidosis; CI, Confidence intervals; CMR, Cardiovascular magnetic resonance; DOR, Diagnostic odds ratio; ECG, Electrocardiography; ECV, Extracellular volume; EMB, Endomyocardial biopsy; LGE, Late gadolinium enhancement; NLR, Negative likelihood ratios; PLR, Positive likelihood ratios; PSIR, Phase-sensitive inversion recovery; QUADAS–2, Quality Assessment of Diagnostic Accuracy Studies–2; RT, Relaxation time; SID, Signal intensity decay; SROC, Summary receiver operating characteristics.
This research received no grant from any funding agency in the public, commercial or not–for–profit sectors.
Availability of data and materials
All the data supporting findings is contained within the manuscript.
LZ participated in the study design and data analysis and drafted the manuscript. ZT helped in the coordination and helped draft the manuscript. QF helped draft the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, Salvi F, Maurer MS. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20:117–24.View ArticlePubMedGoogle Scholar
- Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2012;19:167–70.View ArticlePubMedGoogle Scholar
- Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12:91–102.View ArticlePubMedGoogle Scholar
- Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, Jaccard A. Cardiac amyloidosis. Updates in diagnosis and management. Arch Cardiovasc Dis. 2013;106:528–40.View ArticlePubMedGoogle Scholar
- Yusuf SW, Solhpour A, Banchs J, Lopez-Mattei JC, Durand J, Iliescu C, Hassan SA, Qazilbash MH. Cardiac amyloidosis. Expert Rev Cardiovasc Ther. 2014;12:265–77.View ArticlePubMedGoogle Scholar
- Sharma N, Howlett J. Current state of cardiac amyloidosis. Curr Opin Cardiol. 2013;28:242–8.View ArticlePubMedGoogle Scholar
- Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129:1840–9.View ArticlePubMedGoogle Scholar
- Sher T, Gertz MA. Recent advances in the diagnosis and management of cardiac amyloidosis. Futur Cardiol. 2014;10:131–46.View ArticleGoogle Scholar
- Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2013;62:e147–239.Google Scholar
- Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95:535–7.View ArticlePubMedGoogle Scholar
- Cappelli F, Baldasseroni S, Bergesio F, Perlini S, Salinaro F, Padeletti L, Attana P, Paoletti PA, Moggi PA, Grifoni E, Fabbri A, Marchionni N, Gensini GF, Perfetto F. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis. Clin Cardiol. 2015;38:69–75.View ArticlePubMedGoogle Scholar
- Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015;20:133–44.View ArticlePubMedGoogle Scholar
- Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M. Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis. J Am Coll Cardiol Img. 2010;3:155–64.View ArticleGoogle Scholar
- Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.View ArticlePubMedGoogle Scholar
- Hosch W, Bock M, Libicher M, Ley S, Hegenbart U, Dengler TJ, Katus HA, Kauczor HU, Kauffmann GW, Kristen AV. MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol. 2007;42:636–42.View ArticlePubMedGoogle Scholar
- Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. J Am Coll Cardiol Img. 2013;6:488–97.View ArticleGoogle Scholar
- Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U. Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. J Am Coll Cardiol. 2008;51:1022–30.View ArticlePubMedGoogle Scholar
- White JA, Kim HW, Shah D, Fine N, Kim K, Wendell DC, Al-Jaroudi W, Parker M, Patel M, Gwadry-Sridhar F, Judd RM, Kim RJ. CMR Imaging With Rapid Visual T1 Assessment Predicts Mortality in Patients Suspected of Cardiac Amyloidosis. J Am Coll Cardiol Img. 2014;7:143–56.View ArticleGoogle Scholar
- Austin BA, Tang WHW, Rodriguez ER, Tan C, Flamm SD, Taylor DO, Starling RC, Desai MY. Delayed Hyper-Enhancement Magnetic Resonance Imaging Provides Incremental Diagnostic and Prognostic Utility in Suspected Cardiac Amyloidosis. J Am Coll Cardiol Img. 2009;2:1369–77.View ArticleGoogle Scholar
- Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Starling RC, Desai MY. Diagnostic and Prognostic Utility of Cardiovascular Magnetic Resonance Imaging in Light-Chain Cardiac Amyloidosis. Am J Cardiol. 2009;103:544–9.Google Scholar
- Aquaro GD, Pugliese NR, Perfetto F, Cappelli F, Barison A, Masci PG, Passino C, Emdin M. Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. Int J Cardiovasc Imaging. 2014;30:1105–15.View ArticlePubMedGoogle Scholar
- Di Bella G, Pizzino F, Minutoli F, Zito C, Donato R, Dattilo G, Oreto G, Baldari S, Vita G, Khandheria BK, Carerj S. The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging. 2014;15:1307–15.View ArticlePubMedGoogle Scholar
- Nakahashi T, Arita T, Yamaji K, Inoue K, Yokota T, Hoshii Y, Fukunaga M, Nomura A, Watanabe H, Miura S, Isotani A, Soga Y, Ando K, Iwabuchi M, Yokoi H, Nosaka H, Yamagishi M, Nobuyoshi M. Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy. Int J Cardiol. 2014;176:753–9.View ArticlePubMedGoogle Scholar
- Deux JF, Damy T, Rahmouni A, Mayer J, Plante-Bordeneuve V. Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study. Amyloid. 2014;21:246–55.View ArticlePubMedGoogle Scholar
- Maceira AM. Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2005;111:186–93.View ArticlePubMedGoogle Scholar
- Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3:155–64.View ArticlePubMedGoogle Scholar
- Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7:133–42.View ArticlePubMedGoogle Scholar
- Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36:244–51.View ArticlePubMedGoogle Scholar
- Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157–65.View ArticlePubMedGoogle Scholar
- Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34–9.View ArticlePubMedGoogle Scholar
- Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012;5:897–907.View ArticlePubMedPubMed CentralGoogle Scholar